EGFR and breast cancer: As a predictive biomarker for EGFR inhibitors in colorectal cancer (Gbenedio et al., 2019), RasGRP1 has been linked to several cancer-related processes, such as hepatocarcinoma carcinogenesis (Zhang et al., 2024) and displaying an association with improved overall survival in breast cancer (Wang B. et al., 2018).